Organon and Co
508
2
3
475
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
5.9%
30 terminated/withdrawn out of 508 trials
94.1%
+7.6% vs industry average
78%
398 trials in Phase 3/4
55%
263 of 475 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (508)
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Role: lead
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Role: lead
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
Role: lead
An Explorative Trial to Explore the Safety, Acceptability and Vaginal Bleeding Pattern of Three Etonogestrel-releasing Medicated Intrauterine Systems (Study P06060)
Role: lead
Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma
Role: collaborator
A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060)
Role: lead
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
Role: lead
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
Role: lead
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
Role: lead
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
Role: lead
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)
Role: lead
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
Role: lead
Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Role: lead
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Role: lead
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
Role: lead
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
Role: lead
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Role: lead
Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)
Role: lead
A Study of E6005 in Japanese Patients With Atopic Dermatitis
Role: lead
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
Role: lead